Thesis (Ph. D.)--West Virginia University, 2005. / Title from document title page. Document formatted into pages; contains ix, 226 p. : ill. (some col.). Vita. Includes abstract. Includes bibliographical references (p. 204-212).

No description available.

by Keung Ka Man. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2003. / Includes bibliographical references (leaves 163-184). / Abstracts in English and Chinese. / Abstract --- p.ii / 摘要 --- p.iv / Acknowledgements --- p.vi / Table of Contents --- p.vii / List of Abbreviations --- p.xiv / List of Tables --- p.xvi / List of Figures --- p.xvi / Chapter CHAPTER 1. --- INTRODUCTION / Chapter 1.1. --- Events happened after brain injury --- p.1 / Chapter 1.2. --- Glial cells --- p.3 / Chapter 1.2.1. --- Microglia --- p.4 / Chapter 1.2.2. --- Oligodendrocytes --- p.5 / Chapter 1.2.3. --- Astrocytes --- p.5 / Chapter 1.2.3.1. --- Uptake of neurotransmitters --- p.7 / Chapter 1.2.3.2. --- Maintenance of extracellular homeostasis --- p.8 / Chapter 1.2.3.3. --- Induction of blood-brain-barrier --- p.8 / Chapter 1.2.3.4. --- Guidance of migrating neurons during development --- p.9 / Chapter 1.2.3.5. --- Immunocompetent cells of the brain --- p.9 / Chapter 1.2.3.6. --- Contribution to astrogliosis --- p.10 / Chapter 1.3. --- Cytokines and astrogliosis --- p.11 / Chapter 1.3.1. --- IL-6 and astrogliosis --- p.12 / Chapter 1.3.2. --- IL-1 and astrogliosis --- p.13 / Chapter 1.3.3. --- IFN-γ and astrogliosis --- p.14 / Chapter 1.3.4. --- TNF-α and astrogliosis --- p.14 / Chapter 1.3.4.1. --- General properties of TNF-α --- p.15 / Chapter 1.3.4.2. --- TNF receptors (TNFRs) --- p.17 / Chapter 1.3.4.3. --- NFkB induction --- p.18 / Chapter 1.3.4.4. --- Intermediate early genes --- p.19 / Chapter 1.3.4.5. --- iNOS is the target of NFkB and AP-1 --- p.20 / Chapter 1.4. --- β-Adrenergic receptors (P-ARs) --- p.21 / Chapter 1.4.1. --- β-ARs and astrogliosis --- p.22 / Chapter 1.4.2. --- General properties of β-ARs --- p.23 / Chapter 1.4.3. --- Interactions between β-adrenergic mechanism and TNF-α --- p.24 / Chapter 1.5. --- Aims and scopes of the project --- p.25 / Chapter CHAPTER 2. --- MATERIALS & METHODS / Chapter 2.1. --- Materials --- p.29 / Chapter 2.1.1. --- Rats for astrocyte culture --- p.29 / Chapter 2.1.2. --- Cell culture materials --- p.29 / Chapter 2.1.2.1. --- Complete Dulbecco's Modified Eagle Medium:F12 (DF12) --- p.29 / Chapter 2.1.2.2. --- Phosphate buffered saline (PBS) --- p.30 / Chapter 2.1.3. --- Drugs preparation --- p.30 / Chapter 2.1.3.1. --- Recombinant cytokines --- p.30 / Chapter 2.1.3.2. --- Modulators of protein kinase A (PKA) --- p.30 / Chapter 2.1.3.3. --- Modulators of protein kinase C (PKC) --- p.31 / Chapter 2.1.3.4. --- β-Agonists and -antagonists --- p.31 / Chapter 2.1.3.5. --- Antibodies used in western blot analysis --- p.31 / Chapter 2.1.4. --- Reagents for cell proliferation determination --- p.32 / Chapter 2.1.5. --- Reagents for RNA isolation --- p.32 / Chapter 2.1.6. --- Reagents for reverse transcription-polymerase chain reaction (RT-PCR) --- p.32 / Chapter 2.1.7. --- Reagents for Electrophoresis --- p.33 / Chapter 2.1.8. --- Reagents and buffers for western blotting --- p.35 / Chapter 2.2. --- Methods --- p.36 / Chapter 2.2.1. --- Preparation of primary astrocytes --- p.36 / Chapter 2.2.2. --- Preparation of cells for assays --- p.36 / Chapter 2.2.3. --- Determination of cell proliferation --- p.36 / Chapter 2.2.3.1. --- [3H]-Thymidine incorporation assay --- p.37 / Chapter 2.2.3.2. --- MTT assay --- p.37 / Chapter 2.2.3.3. --- Data analysis --- p.38 / Chapter 2.2.4. --- Determination of RNA expression by RT-PCR analysis --- p.38 / Chapter 2.2.4.1. --- RNA extraction --- p.38 / Chapter 2.2.4.2. --- Spectrophotometric Quantitation of DNA and RNA --- p.38 / Chapter 2.2.4.3. --- RNA gel electrophoresis --- p.39 / Chapter 2.2.4.4. --- Reverse transcription-polymerase chain reaction (RT-PCR) --- p.39 / Chapter 2.2.4.5. --- Separation of PCR products by agarose gel electrophoresis --- p.40 / Chapter 2.2.4.6. --- Quantification of band density --- p.41 / Chapter 2.2.5. --- Determination of protein expression by Western blotting --- p.41 / Chapter 2.2.5.1. --- Total protein extraction --- p.41 / Chapter 2.2.5.2. --- Western blotting analysis --- p.42 / Chapter CHAPTER 3. --- RESULTS / Chapter 3.1. --- Effects of pro-inflammatory cytokines on astrocyte proliferation --- p.43 / Chapter 3.1.1. --- Effects of TNF-α on astrocyte proliferation --- p.44 / Chapter 3.1.2. --- Effects of TNF-R1 and -R2 antibodies on astrocyte proliferation --- p.47 / Chapter 3.1.3. --- Effects of other cytokines on astrocyte proliferation --- p.50 / Chapter 3.1.4. --- Comparisons of the effects of cytokines on astrocyte proliferation --- p.53 / Chapter 3.2. --- Effects of β-agonist and -antagonist on astrocyte proliferation --- p.55 / Chapter 3.3. --- Effects of TNF-α on the expression of TNFR and endogenous TNF-α in astrocytes --- p.60 / Chapter 3.3.1. --- Effects of TNF-α on the expression of TNF-R1 and -R2 in astrocytes --- p.60 / Chapter 3.3.1.1. --- Effects of TNF-α on the expression of TNF-R1 and -R2 mRNA --- p.60 / Chapter 3.3.1.2. --- TNFR subtypes involved in the TNF-α-induced TNF-R2 mRNA expression --- p.62 / Chapter 3.3.1.3. --- Signaling pathways of the TNF-α-induced TNF-R2 mRNA expression --- p.67 / Chapter 3.3.1.4. --- Effects of TNF-α on the expression of TNF-R1 and -R2 --- p.68 / Chapter 3.3.2. --- Effects of TNF-α on the expression of endogenous TNF-α in astrocytes --- p.73 / Chapter 3.3.2.1. --- Effects of TNF-α on the expression of TNF-α mRNA --- p.73 / Chapter 3.3.2.2. --- TNFR subtypes involved in the TNF-α-induced TNF-α mRNA expression --- p.73 / Chapter 3.3.2.3. --- Signaling pathways of the TNF-α-induced TNF-α mRNA expression --- p.74 / Chapter 3.3.2.4. --- Effects of other cytokines on the expression of TNF-α mRNA --- p.75 / Chapter 3.4. --- Effects of TNF-α on the expression of β1- and β2-AR in astrocytes --- p.85 / Chapter 3.4.1. --- Effects of TNF-α on the expression of β1- and β2-AR mRNA --- p.85 / Chapter 3.4.2. --- TNFR subtypes involved in the TNF-a-induced β1 and β2-AR mRNA expressions --- p.88 / Chapter 3.4.3. --- Signaling pathways of the TNF-α -induced β1- and β2-AR mRNA expressions --- p.88 / Chapter 3.4.4. --- Effects of TNF-α on the expression of β1- and β2-AR protein --- p.100 / Chapter 3.4.5. --- Effects of other cytokines on the expression of β1- and β2-AR mRNA --- p.100 / Chapter 3.5. --- Interactions between TNF-α and β-adrenergic mechanism in astrocytes --- p.107 / Chapter 3.5.1. --- Effects of β-agonists and -antagonists on the TNF-α-induced endogenous TNF-α expression in astrocytes --- p.107 / Chapter 3.5.1.1. --- Effects of ISO and PROP on the expression of TNF-α mRNA --- p.107 / Chapter 3.5.1.2. --- β-AR subtypes involved in the TNF-α-induced TNF-α mRNA expression --- p.108 / Chapter 3.5.2. --- Effects of β-agonists and -antagonists on the TNF-α-induced TNFRs expression in astrocytes --- p.112 / Chapter 3.5.2.1. --- Effects of ISO and PROP on the expression of TNFRs mRNA --- p.112 / Chapter 3.5.2.2. --- β-AR subtypes involved in the TNF-α-induced TNF-R2 mRNA expression --- p.115 / Chapter 3.6. --- Effects of TNF-α on the expression of transcription factors in astrocytes --- p.117 / Chapter 3.6.1. --- "Effects of TNF-α on c-fos, c-jun and NFKB/p50 expression" --- p.118 / Chapter 3.6.2. --- Effects of other cytokines on the expression of NFKB/p50 mRNA --- p.119 / Chapter 3.6.3. --- "TNFR subtypes involved in the TNF-α-induced c-fos, c-jun and NFKB/p50 mRNA expression" --- p.125 / Chapter 3.7. --- Effects of TNF-α on the expression of iNOS in astrocytes --- p.130 / Chapter 3.7.1. --- Effects ofTNF-α the expression of iNOS mRNA --- p.130 / Chapter 3.7.2. --- TNFR subtypes involved in the TNF-α-induced iNOS mRNA expression --- p.131 / Chapter 3.7.3. --- Signaling pathways of the TNF-α-induced iNOS mRNA expression --- p.136 / Chapter 3.7.4. --- Effects of other cytokines on the expression of iNOS mRNA --- p.139 / Chapter 3.7.5. --- Effects of β-agonists and -antagonists on the TNF-α-induced iNOS expression --- p.142 / Chapter 3.7.5.1. --- Effects of ISO and PROP on the expression of iNOS mRNA --- p.142 / Chapter 3.7.5.2. --- β-AR subtypes involved in the TNF-α-induced iNOS mRNA expression --- p.143 / Chapter CHAPTER 4. --- DISCUSSIONS & CONCLUSIONS / Chapter 4.1. --- Effects of TNF-α on astrocyte proliferation --- p.148 / Chapter 4.2. --- Roles of endogenous TNF-α and TNFR in astrocyte proliferation --- p.150 / Chapter 4.3. --- Interactions between TNF-α and β-adrenergic mechanism in astrocytes --- p.154 / Chapter 4.4. --- Induction of transcription factors by TNF-α in astrocytes --- p.157 / Chapter 4.5. --- Possible source of β-agonists --- p.159 / Chapter 4.6. --- Conclusions --- p.160 / REFERENCE --- p.163

Thesis (Ph.D. in Immunology) -- University of Colorado, 2005. / Typescript. Includes bibliographical references (leaves 190-212). Free to UCDHSC affiliates. Online version available via ProQuest Digital Dissertations;

No description available.

The a of TNFa in title is the Greek alpha. / Thesis (MSc)--University of Stellenbosch, 2002. / ENGLISH ABSTRACT: Background: Cardiac hypertrophy is an adaptive process occurring in response to mechanical overload or tissue injury. The stimuli for cardiac hypertrophy are diverse and vary from increased afterload on the heart to cardiac remodeling in response to cytokines. Amongst others, obesity is characterized by excessive body weight resulting in metabolic disorders. This excess body weight necessitates an increased blood and oxygen delivery to the peripheral tissues, which is achieved by an elevated cardiac output. Total blood volume is also increased in the obese due to the increased tissue volume and vascularity. With time, the obesity induced increase in cardiac preload results in left ventricular hypertrophy and dilatation. Obesity is also associated with complications such as hypertension, insulin resistance and impaired glucose metabolism. In addition, adipose tissue has been implicated to contribute to elevated circulating TNFa levels in obesity and may contribute to the pathophysiology of the heart in obese individuals. The heart is a major cytokine-producing organ that generates amongst others tumor necrosis factor a (TNFa). TNFa is a proinflammatory cytokine, which acts to increase its own production, has cytotoxic and cytostatic effects on certain tumor cells and influences growth and differentiation in virtually all cell types including cardiomyocytes. Elevated levels of TNFa are detected peripherally in almost all forms of cardiac injury and in hypertrophic cardiomyopathy. These elevations are proposed to be deleterious to the heart, although an adaptive role for low levels of TNFa has been proposed. Aim: The aim of the study was to determine whether there is a correlation between obesity and serum, myocardial, and adipose tissue TNFa levels and cardiac hypertrophy. We also wished to determine whether the hearts from the obese animals functioned normally under normoxic conditions and whether they responded differently to ischaemia/reperfusion when compared with their concurrent controls. Materials and Methods: Male Sprague-Dawley rats (n=100) were fed a high caloric diet (HCD) containing 33% rat chow, 33% condensed milk, 7% sucrose and 27% water, or standard laboratory rat chow for 6-12 weeks. Food consumption, body weight gain, heart weight and tibia length were measured. Serum glucose, insulin and lipid levels were also determined. Hearts were excised and perfused on the isolated Working Heart perfusion apparatus and cardiac function was monitored and documented. Hearts were then subjected to 15 minutes of total global ischaemia at 370C, and reperfused for 30 minutes. Cardiac function was again documented. A separate series of hearts were freeze-clamped at different time points during the experimental protocol and stored in liquid nitrogen for the determination of myocardial TNFa and cGMP levels. Serum TNFa levels were determined after 12 weeks on the high caloric or normal/control diet. After 12 weeks on the diet myocardial TNFa levels of the HCD fed animals and their concurrent controls were determined before and during ischaemia. Adipose tissue and myocardial tissue TNFa levels were also determined after 6, 9 and 12 weeks on the respective diets. Myocardial cGMP levels were measured in the HCD fed rats and the control rats after 6, 9, and 12 weeks. These data were used as an indirect index to determine whether the myocardial NOcGMP pathway was activated in the normoxic hearts on the respective diets. Results: The body weight of the HCO fed animals was significantly higher compared with their respective controls after 12 weeks on the diet (459.9 ± 173.8 g and 271.5 ± 102.6 g respectively (p<0.05». The HCO fed animals also had heart weight to body weight ratios that were significantly greater compared with the controls (4.2 ± 0.1 mglg and 3.7 ± 0.1 mglg respectively (p<0.05». The plasma glucose levels of the HCO fed animals were higher than their respective controls (9.2 ± 0.3 mmoiII and 7.8 ± 0.3 mmoiII respectively (p<0.05)), but their insulin levels were similar (12.87 ± 1.02 IlIUlml and 12.42 ± 5.06 IlIU/ml). Plasma lipid profiles (plasma cholesterol, high density lipoprotein (HOL) cholesterol and plasma triacylglyceride (TAG)) were abnormal in the HCO fed animals compared with the control rats. Plasma TAG levels in the HCO fed animals were significantly higher compared with the control rats (0.664 ± 0.062 mmoiII and 0.503 ± 0.043 (p<0.05», while plasma cholesterol levels (1.794 ± 0.058 mmoIII and 2.082 ± 0.062 mmoiII (p<0.05» and HOL cholesterol levels were significantly lower (1.207 ± 0.031 mmoiII and 1.451 ± 0.050 mmoiII (p<0.05». Cardiac mechanical function was similar for both groups before ischaemia, but the percentage aortic output recovery was lower for the hearts from the HCO fed animals when compared with their controls (47.86 ± 7.87% and 66.67 ± 3.76 % respectively (p<0.05». Serum TNFa levels of the HCO fed animals were higher compared with the control animals (51.04 ± 5.14 AU and 31.46 ± 3.72 AU respectively (p<0.05», but myocardial TNFa levels remained lower in these animals (312.0 ± 44.7 pglgram ww and 571.4 ± 132.9 pg/gram ww respectively (p<0.05)). During ischaemia these myocardial TNFa levels increased above those of the controls (442.9 ± 12.4 pg/gram ww and 410.0 ± 12.5 pg/gram ww respectively (p<0.05)). The adipose tissue TNFa levels were significantly increased after 12 weeks on the high caloric diet compared with the control animals (4.4 ± 0.4 pg/gram ww and 2.5 ± 0.3 pg/gram ww respectively (p<0.05)). There was no significant difference in the myocardial cGMP levels of the HCD rats compared with the conrol rats after 6, 9 and 12 weeks. Conclusion: 1) The high caloric diet induced obesity, which lead to cardiac hypertrophy in this study. 2) There was a strong correlation between elevated adipose tissue and serum TNFa levels, and cardiac hypertrophy. 3) Elevated serum TNFa levels did not lead to activation of the myocardial NO-cGMP pathway in the normoxic hearts in this model. 4) The hypertrophied hearts from the HCD fed animals had poorer post-ischaemie myocardial functions than their concurrent controls. / AFRIKAANSE OPSOMMING: Agtergrond: Miokardiale hipertrofie is In aanpassing wat gebeur as In gevolg van meganiese oorbelading of weefsel beskadiging. Verskillende stimuli kan tot miokardiale hipertrofie aanleiding gee soos byvoorbeeld In verhoging in nalading, of miokardiale hermodellering in respons op sitokiene. Verhoging van voorbelading in vetsug mag ook tot hipertrofie aanleiding gee. Vetsug word gekenmerk deur In oormatige liggaamsmassa wat tot metaboliese versteurings lei. Die oormatige liggaamsmassa vereis In verhoging in bloed- en suurstofverskaffing aan die perifere weefsel wat deur In verhoging in die kardiale uitset vermag kan word. Die bloed volume van In vetsugtige individu word ook verhoog as gevolg van In verhoging in weefselvolume en vaskulariteit en met verloop van tyd induseer die verhoogde kardiale voorbelading linker ventrikulêre hipertrofie en dilatasie. Vetsug word ook met verskeie ander siekte toestande soos hipertensie, insulien weerstandigheid en versteurde glukose metabolisme, geassosieer. Vetweefsel dra ook by tot verhoging van tumor nekrose faktor alfa (TNFa) vlakke in die bloed, wat op sy beurt tot miokardiale hipertrofie mag bydra. TNFa is In proinflammatoriese sitokien wat sy eie produksie kan stimuleer. Dit het ook sitotoksiese en sitostatiese effekte op sekere tumor selle en kan groei en differensiasie in bykans alle seltipes, insluitende kardiomiosiete, stimuleer. Die hart kan ook TNFa produseer en verhoogde TNFa vlakke word feitlik in alle vorms van miokardiale besering en hipertrofiese kardiomiopatie waargeneem. Daar word voorgestel dat verhoogde TNFa vlakke vir die hart nadelig is, ten spyte van die vermoeding dat die sitokien In potensiële aanpassings rol by laer vlakke het. Doelstelling: Die doel van hierdie studie was om vas te stelof daar 'n verband tussen vetsug en serum, miokardiale en vetweefsel TNFa vlakke en miokardiale hipertrofie, bestaan. Ons het ook gepoog om te bepaal of harte van vetsugtige diere normaal funksioneer en of die response van sulke harte op isgemie-herperfusie van die van ooreenstemmende kontroles verskil. Materiaal en tegnieke: Manlike Sprague-Dawley rotte (n=100) is vir 6-12 weke op 'n hoë kalorie dieët (HKD) geplaas. Die HKD het uit 33% rotkos, 33% gekondenseerde melk, 7% sukrose en 27% water bestaan. Kontrole diere het standaard laboratorium rotkos ontvang. Voedselinname, liggaamsmassa toename, serum insulien, glukose en lipied vlakke is ook bepaal. Harte is geïsoleer en geperfuseer volgens die Werk Hart perfusie metode en hart funksie is gemonitor en gedokumenteer. Harte is vervolgens aan 15 minute globale isgemie by 3rC blootgestel en daarna weer vir 30 minute geherperfuseer waartydens hartfunksie weer gedokumenteer is. 'n Aparte groep harte is op spesifieke tydsintervalle gedurende die eksperimentele protokol gevriesklamp en in vloeibare stikstof gestoor vir die bepaling van miokardiale TNFa en sGMP vlakke. Serum TNFa vlakke is bepaal na 12 weke op die dieët. Na die diere 12 weke op die HKD was, is hierdie diere en hulooreenstemmende kontroles se miokardiale TNFa vlakke voor en na isgemie bepaal. Vetweefsel en miokardiale TNFa vlakke is ook onderskeidelik na 6, 9 en 12 weke bepaal. Miokardiale sGMP vlakke is in die HKD diere en in die kontrole diere na 6, 9 en 12 weke bepaal. sGMP vlakke is gebruik as 'n indirekte indeks van aktivering van die miokardiale NO-sGMP boodskapper pad. Resultate: Na 12 weke op die dieët was die liggaamsmassa van die HKD diere beduidend hoër in vergeleke met hulooreenstemmende kontroles (459.9 ± 173.8 g en 271.5 ± 102.6 g (p<0.05)). Die HKD diere se hart massa tot liggaam massa verhouding was ook beduidend hoër in vergelyking met die van kontroles (4.2 ± 0.1 mglg en 3.7 ± 0.1 mglg (p<0.05)). Alhoewel insulien vlakke dieselfde was (12.42 ± 5.06 j.lIU/ml en 12.87 ± 1.02 j.lIU/ml), was serum glukose vlakke van die HKD diere hoër as die van die ooreenstemmende kontroles (9.2 ± 0.3 mmoiii en 7.8 ± 0.3 mmoiii (p<0.05)). Plasma lipied profiele (HOL cholesterol, plasma cholesterol en trigliseriede) was abnormaal in die HKD diere. Plasma TAG vlakke in die HKD diere was beduidend hoër as die van die kontroles (0.664 ± 0.062 mmoiii en 0.503 ± 0.043 (p<0.05)), terwyl plasma cholesterol vlakke (1.794 ± 0.058 mmoiii en 2.082 ± 0.062 mmoiii (p<0.05)) en HOL cholesterol vlakke beduidend laer was (1.207 ± 0.031 mmoiii en 1.451 ± 0.050 mmoiii (p<0.05)). Miokardiale meganiese funksie was dieselfde vir beide groepe voor isgemie, maar die persentasie aorta omset herstel tydens herperfusie was laer in die HKD diere in vergelyking met die van kontrole diere (47.86 ±. 7.87% en 66.67 ± 3.76% (p<0.05)). Serum TNFa vlakke van die HKD diere was beduidend hoër as die van kontrole diere (51.04 ± 5.14 AU en 31.46 ± 3.72 AU (p<0.05)), maar miokardiale TNFa vlakke was laer (312.0 ± 44.7 pglgram nat gewig en 571.4 ± 132.9 pglgram nat gewig (p<0.05)). Die vetweefsel TNFa vlakke was ook beduidend verhoog na 12 weke op "n hoë kalorie dieët wanneer dit vergelyk word met die van kontrole diere (4.4 ± 0.4 pglgram nat gewig en 2.5 ± 0.3 pglgram nat gewig respektiewelik (p<0.05)). Daar was geenbeduidende verskille in die miocardiale vlakke van sGMP in die HKD diere in vergelyking met die kontroles na 6, 9 en 12 weke. Gevolgtrekkings: 1) "n Hoë kalorie dieët het in dié studie vetsug geïnduseer en tot miokardiale hipertrofie gelei. 2) Daar was "n positiewe korrelasie tussen verhoogde vetweefsel en serum TNFa vlakke, en miokardiale hipertrofie. 3) Verhoogde serum TNFa vlakke het nie tot die aktivering van die miokardiale NO-sGMP pad in hierdie model gelei nie. 4) Die hipertrofiese harte het tydens herperfusie ná isgemie swakker as hulooreenstemmende kontroles gefunksioneer.

published_or_final_version / abstract / Pathology / Master / Master of Philosophy

published_or_final_version / abstract / Surgery / Master / Master of Philosophy

by Kwan, Leo. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1995. / Includes bibliographical references (leaves 108-116). / Abstract --- p.i / Achnowledgment --- p.ii / List of abbreviations --- p.iii / List of table and figures --- p.v / Table of contents --- p.vi / Chapter CHAPTER 1 --- INTRODUCTION / Chapter 1.1 --- THE DISCOVERY OF TUMOUR NECROSIS FACTOR (TNF) --- p.1 / Chapter 1.2 --- THE MOLECULE AND ITS RECEPTORS --- p.1 / Chapter 1.3 --- THE BIOLOGICAL ACTIVITIES OF TNF --- p.3 / Chapter 1.4 --- STUDIES ON THE CYTOTOXIC MECHANISM OF TNF --- p.4 / Chapter 1.5 --- A TENTATIVE MECHANISM OF TNF CYTOTOXICITY --- p.11 / Chapter 1.6 --- THE GLUTATHIONE SYSTEM : A CELLULAR PROTECTIVE MECHANISM AGAINST OXIDATIVE STRESS …… --- p.12 / Chapter 1.7 --- OBJECTIVE AND STRATEGY OF THIS STUDY --- p.16 / Chapter CHAPTER 2 --- MATERIALS AND APPARATI / Chapter 2.1 --- CELL LINES --- p.19 / Chapter 2.2 --- "ISOLATION, MAINTENANCE AND SUBCULTURE OF CELL LINES" --- p.19 / Chapter 1. --- Plain RPMI-1640 medium / Chapter 2. --- Penicillin-streptomycin solution / Chapter 3. --- Foetal bovine serum / Chapter 4. --- Complete RPMI-1640 medium / Chapter 5. --- Trypsin-ethylenediaminetetraacetate solution / Chapter 6. --- Phosphate buffered saline / Chapter 7. --- Cycloheximide / Chapter 8. --- Actinomycin D / Chapter 9. --- Trypan blue stain / Chapter 10. --- Neutral red stain / Chapter 11. --- Recombinant human tumour necrosis factor / Chapter 12. --- Cell culture plates and flasks / Chapter 2.3 --- GROWTH CHARACTERISTIC --- p.22 / Chapter 1. --- Tritiated Thymidine / Chapter 2. --- Tritiated Leucine / Chapter 3. --- Trichloroacetic acid / Chapter 4. --- Scintillation cocktail / Chapter 2.4 --- "RESPONSE TOWARDS ANTICANCER DRUGS, CYTOTOXIC AGENTS, AND ENZYME MODULATORS" --- p.23 / Chapter 1. --- N-acetyl-DL-homocysteinethiolactone / Chapter 2. --- Diethyldithiocarbamic acid / Chapter 3. --- Doxorubicin / Chapter 4. --- Acivicin / Chapter 5. --- Ethacrynic acid / Chapter 6. --- "L'Buthionine-[S,R]-sulfoximine" / Chapter 7. --- Hydrogen peroxide / Chapter 8. --- Methotrexate / Chapter 9. --- Menadione / Chapter 2.5 --- CULTURE OF BACTERIAL CELLS --- p.27 / Chapter 1. --- Ampicillin stock solution / Chapter 2. --- Chloramphenicol stock solution / Chapter 3. --- Tetracycline stock solution / Chapter 4. --- Luria-Bertani medium / Chapter 5. --- LB with ampicillin / Chapter 6. --- SOB medium / Chapter 7. --- SOB medium with ampicillin / Chapter 8. --- SOC medium / Chapter 9. --- SB medium / Chapter 10. --- SB medium with ampicillin / Chapter 11. --- Agar plates / Chapter 2.6 --- PREPARATION OF DNA PROBES FROM BACTERIAL CLONES --- p.29 / Chapter 1. --- FlexiPrep Kit / Chapter 2. --- Restriction endonucleases / Chapter 3. --- GeneClean® II Kit / Chapter 4. --- cDNA clones for making DNA probes / Chapter 5. --- TrisHCl EDTA buffer / Chapter 2.7. --- ELECTROPHORESIS OF DNA --- p.31 / Chapter 1. --- EDTA stock solution / Chapter 2. --- Tris acetate EDTA electrophoresis buffer / Chapter 3. --- Tris borate EDTA electrophoresis buffer / Chapter 4. --- Ethidium bromide / Chapter 5. --- DNA molecular size markers / Chapter 6. --- TAE/TBE agarose gel slab / Chapter 2.8 --- CONSTRUCTION OF MURINE TNFR1 PARTIAL cDNA CLONE --- p.33 / Chapter 1. --- Frist strand cDNA synthesis Kit / Chapter 2. --- Murine TNFR1 forward and reverse primers / Chapter 3. --- Polymerase chain reaction reagents / Chapter 4. --- Cloning vector / Chapter 5. --- Modifing enzymes / Chapter 6. --- T7 SequencingTM Kit / Chapter 7. --- Acrylamide/bis gel stock solution / Chapter 8. --- Urea / Chapter 9. --- TEMED and ammonium persulphate / Chapter 10. --- β-Galactosidase colour test reagents / Chapter 11. --- TFB solution / Chapter 12. --- DnD solution / Chapter 2.9. --- RADIOLABELLING OF DNA PROBES --- p.35 / Chapter 1. --- Oligolabelling kit / Chapter 2. --- Redivue [α-32P] dCTP / Chapter 3. --- PUSH column / Chapter 2.10 --- EXTRACTION OF TOTAL RNA FROM CELL LINES --- p.36 / Chapter 1. --- N-Lauroylsarcosine / Chapter 2. --- 2M sodium acetate (pH48) / Chapter 3. --- Phenol / Chapter 4. --- Isopropanol / Chapter 5. --- Ethanol / Chapter 6. --- Extraction buffer / Chapter 7. --- Chloroform / Chapter 8. --- Isoamyl alcohol / Chapter 2.11 --- HYBRIDIZATION AND NORTHERN ANALYSIS --- p.37 / Chapter 1. --- 20XSSC / Chapter 2. --- 5X formaldehyde running buffer / Chapter 3. --- RNA sample buffer / Chapter 4. --- 10X RNA loading buffer / Chapter 5. --- Formaldehyde slab gel / Chapter 6. --- Hybond®-N membrane / Chapter 7. --- Immobilon®-N membrane / Chapter 8. --- Salmon sperm DNA / Chapter 9. --- Sodium dodecyl sulphate / Chapter 10. --- Dextran sulphate / Chapter 11. --- Kodak Biomax MR and X-OMAT films and developing kits / Chapter 2.12 --- APPARATI USED --- p.39 / Chapter CHAPTER 3 --- METHODS / Chapter 3.1 --- ISOLATION AND MAINTENANCE OF TNF RESISTANT L929 CELLS --- p.40 / Chapter 3.1.1 --- Culture of L929 cells / Chapter 3.1.2 --- Trypan blue exclusion test / Chapter 3.1.3 --- Isolation of TNF-resistant variants of L929 / Chapter 3.1.4 --- Verification of the TNF-resistant trait of rL929 / Chapter 3.1.5 --- Neutral red uptake assay / Chapter 3.2 --- COMPARING L929 AND rL929 CELLS IN TERMS OF GROWTH CHARACTERISTICS --- p.43 / Chapter 3.2.1 --- Doubling time / Chapter 3.2.2 --- Rate of protein synthesis / Chapter 3.2.3 --- Rate of DNA synthesis / Chapter 3.3 --- COMPARING L929 AND rL929 CELLS IN TERMS OF RESPONSE TOWARDS DIFFERENT ENZYME INHIBITORS AND CYTOTOXIC AGENTS --- p.44 / Chapter 3.3.1 --- TNF cytotoxicity on L929 and rL929 cells --- p.44 / Chapter 3.3.2 --- Effects of inhibitors of gene transcription and protein synthesis on TNF cytotoxicity on L929 and rL929 cells --- p.44 / Chapter 3.3.3 --- Cytotoxic effect of hydrogen peroxide and menadione on L929 and rL929 cells --- p.44 / Chapter 3.3.4 --- TNF cytotoxicity on L929 and rL929 cells: effect of N-acetyl homocysteine thiolatone --- p.45 / Chapter 3.3.4.1 --- The tolerant limit of AHCT / Chapter 3.3.4.2 --- Effect of AHCT on TNF cytotoxicity / Chapter 3.3.5 --- TNF cytotoxicity on L929 and rL929 cells: effect of diethyldithiocarbamate --- p.46 / Chapter 3.3.5.1 --- The tolerant limit of DEDTC / Chapter 3.3.5.2 --- Effect of DEDTC on TNF cytotoxicity / Chapter 3.3.6 --- TNF cytotoxicity on L929 and rL929 cells: effect of buthionice sulfoximine --- p.47 / Chapter 3.3.6.1 --- The tolerant limit of BSO / Chapter 3.3.6.2 --- Effect of BSO on TNF cytotoxicity / Chapter 3.3.7 --- TNF cytotoxicity on L929 and rL929 cells: effect of Acivicin --- p.47 / Chapter 3.3.7.1 --- The tolerant limit of acivicin / Chapter 3.3.7.2 --- Effect of acivicin on TNF cytotoxicity / Chapter 3.3.8 --- TNF cytotoxicity on L929 and rL929 cells: effect of ethacrynic acid --- p.48 / Chapter 3.3.8.1 --- The tolerant limit of ethacrynic acid / Chapter 3.3.8.2 --- Effect of ethacrynic acid on TNF cytotoxicity / Chapter 3.3.9 --- Cytotoxic effect of doxorubicin on L929 and rL929 cells --- p.49 / Chapter 3.3.10 --- TNF cytotoxicity of L929 cells: effect of N-acetyl cysteine --- p.49 / Chapter 3.3.11 --- Cytotoxic effect of methotrexate on L929 and rL929 cells --- p.50 / Chapter 3.3.12 --- Cytotoxic effect of hyperthermia on L929 and rL929 cells --- p.50 / Chapter 3.4 --- NORTHERN ANALYSIS AND HYBRIDIZATION --- p.51 / Chapter 3.4.1. --- Preparing RNA blots --- p.51 / Chapter 3.4.1.1 --- Extraction of total RNA from cells / Chapter 3.4.1.2 --- Making equal loading of RNA samples in formaldehyde gel electrophoresis / Chapter 3.4.1.3 --- Northern blotting of RNA / Chapter 3.4.2. --- Preparation of cDNA probes --- p.53 / Chapter 3.4.2.1 --- Preparing plasmids from A TCC clones / Chapter 3.4.2.2 --- Preparing TNFR1 probe from first-strand cDNA of L929 cells / Chapter 1. --- Construction of recombinant clone from the PCR product of TNFRl fragment / Chapter 2. --- Transforming the recombinant vector into JM109 host / Chapter 3. --- Sequencing of PCR product for identity confirmation / Chapter 3.4.2.3 --- Preparing DNA inserts from plasmids / Chapter 3.4.3 --- Radiolabelling of cDNA probes --- p.56 / Chapter 3.4.4 --- Hybridization of radioactive probes to RNA blots --- p.57 / Chapter CHAPTER 4 --- RESULTS AND DISCUSSIONS / Chapter 4.1 --- ISOLATION OF TNF-RESISTANT VARIANTS OF L929 CELLS --- p.58 / Chapter 4.1.1 --- Single cell subcloning of TNF-resistant L929 variants / Chapter 4.1.2 --- Growth rates of L929 and rL929 cells / Chapter 4.1.3 --- Rate of protein synthesis in L929 and rL929 cells / Chapter 4.1.4 --- Rate of DNA synthesis in L929and rL929 cells / Chapter 4.2 --- EFFECT OF INHIBITORS OF GENE TRANSCRIPTION AND PROTEIN SYNTHESIS ON TNF CYTOTOXICITY ON L929 AND rL929 CELLS --- p.67 / Chapter 4.3 --- RESPONSE OF L929 AND rL929 CELLS TOWARDS VARIOUS CYTOTOXIC AGENTS --- p.70 / Chapter 4.3.1 --- "Response towards methotrexate, an anti-metabolite used in cancer treatment" / Chapter 4.3.2 --- "Response towards doxorubicin, an chemotherapeutic agent used in cancer treatment" / Chapter 4.3.3 --- "Response towards menadione, a cytotoxic agent known to generate free radicals inside cells" / Chapter 4.3.4 --- Response towards hydrogen peroxide: a highly oxidative agent / Chapter 4.3.5 --- "Response towards hyperthermia, a treatment known to exert oxidative stress on cells" / Chapter 4.4 --- EFFECTS OF MODULATORS OF CYTOSOLIC SUPEROXIDE DISMUTASE ON TNF CYTOTOXICITY ON L929 and rL929 CELLS --- p.77 / Chapter 4.5 --- EFFECT OF MODULATORS OF GLUTATHIONE METABOLISM ON TNF CYTOTOXICITY ON L929 AND rL929 CELLS --- p.82 / Chapter 4.5.1 --- "Effects of L-buthionine [S,R] sulfoximine, an inhibitor of glutathione synthesis" --- p.82 / Chapter 4.5.2 --- "Effect of N-acetyl cysteine, a cysteine derivative" --- p.84 / Chapter 4.5.3 --- "Effects of acivicin , an inhibitor of GSH reuptake and recycle" --- p.85 / Chapter 4.5.4 --- "Effect of ethacrynic acid, an inhibitor of glutathione S- transferase" --- p.87 / Chapter 4.6 --- GENE EXPRESSION IN L929 AND rL929 CELLS IN THE COURSE OF TNF CHALLENGE --- p.89 / Chapter 4.6.1 --- Isolation of total RNA from L929 and rL929 cells --- p.89 / Chapter 4.6.2 --- Preparation of DNA probes for hybridization --- p.89 / Chapter 4.6.3 --- Hybridization of specific probes on RNA blots --- p.90 / Chapter 4.6.3.1 --- Expression of heat shock protein --- p.70 / Chapter 4.6.3.2 --- Expression of the p55 TNF receptor / Chapter 4.6.3.3 --- Expression of glutathione reductase / Chapter 4.6.3.4 --- Expression of glutathione S-transferase pi / Chapter 4.7 --- DISCUSSIONS OF THE EXPERIMENTAL RESULTS --- p.97 / Chapter CHAPTER 5 --- GENERAL DISCUSSION --- p.104 / APPENDIX / Generation of the TNF receptor 1 cDNA probe --- p.106 / REFERENCES --- p.108

by Suk-Fung Tsang. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1993. / Includes bibliographical references (leaves 101-112). / Abstract --- p.i / Acknowledgement --- p.iii / Abbreviation --- p.iv / Chapter Chapter 1 --- Introduction --- p.1 / Chapter 1.1 --- TNF molecule / Chapter 1.2 --- Molecular biosynthesis of TNF / Chapter 1.3 --- Antitumor activity of TNF / Chapter 1.4 --- Macrophage-mediated immunity / Chapter 1.5 --- Endogenous production of TNF / Chapter 1.6 --- LPS : the potent inducer for TNF release / Chapter 1.7 --- Natural product: as primer or inducer / Chapter 1.8 --- Aim of this project / Chapter Chapter 2 --- Materials and Methods --- p.22 / Chapter 2.1 --- Materials / Chapter 2.2 --- Animals / Chapter 2.3 --- Cell line / Chapter 2.4 --- Transformed cell line : EAT cells invivo / Chapter 2.5 --- Reagents / Chapter 2.6 --- Methods / Chapter Chapter 3 --- Preparation of sample --- p.33 / Chapter 3.1 --- Alcohol precipitaion of Bupleuri radix / Chapter 3.2 --- Endogenous TNF production by BR fractions / Chapter Chapter 4 --- Purification of BRI --- p.38 / Chapter 4.1 --- Gel filtration chromatography of BRI / Chapter 4.2 --- Anion exchange chromatography / Chapter Chapter 5 --- Purification of PQI --- p.52 / Chapter 5.1 --- Gel filtration chromatography of PQI / Chapter 5.2 --- Anion exchange chromatography / Chapter Chapter 6 --- Capacity of BR and PQ as eliciting agent for endogenous TNF production --- p.62 / Chapter 6.1 --- Time course of endogenous TNF production by BRI subfractions / Chapter 6.2 --- Time course of endogenous TNF production by PQI subfractions / Chapter 6.3 --- BRI subfractions as eliciting agents / Chapter 6.4 --- PQI subfractions as eliciting agents / Chapter Chapter 7 --- Are BR and PQ priming agents in endogenous TNF production ？ --- p.71 / Chapter 7.1 --- Priming by intraperitoneal route / Chapter 7.2 --- Priming by intravenous route / Chapter Chapter 8 --- Removal of LPS by acetic acid treatment --- p.79 / Chapter Chapter 9 --- Antitumor activities of BRI subfractionsin relationship with TNF production --- p.86 / Chapter 9.1 --- BRI subfraction as eliciting agent / Chapter 9.2 --- Pretreatment with BRIA subfractions followed by LPS treatment / Chapter Chapter 10 --- Conclusion --- p.95 / Bibliography --- p.101